We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-0.32%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$417M
Cap. Flow
-$194M
Cap. Flow %
-20.04%
Top 10 Hldgs %
49.08%
Holding
83
New
26
Increased
6
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$39.6M
2
VTYX
Ventyx Biosciences
VTYX
+$34.6M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$23.2M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.3M
5
ALGS icon
Aligos Therapeutics
ALGS
+$16.8M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$62.9M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$41.7M
3
NKTX icon
Nkarta
NKTX
+$35.5M
4
CMPS
Compass Pathways
CMPS
+$35M
5
BCYC
Bicycle Therapeutics
BCYC
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNCE
26
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$11.3M 1.16%
1,350,000
-650,000
-33% -$5.36M
IPSC icon
27
Century Therapeutics
IPSC
$382M
$9.74M 1%
614,095
-25,000
-4% -$470K
RLMD icon
28
Relmada Therapeutics
RLMD
$546M
$9.01M 0.93%
+400,000
New +$8.89M
PTGX icon
29
Protagonist Therapeutics
PTGX
$8.85B
$8.55M 0.88%
+250,000
New +$7.9M
NGM
30
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$8.41M 0.87%
+475,000
New +$9.11M
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.33M 0.76%
+50,000
New +$7.76M
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$7.22M 0.74%
+625,000
New +$6.97M
TYRA icon
33
Tyra Biosciences
TYRA
$1.88B
$6.66M 0.69%
473,394
-530,000
-53% -$10.5M
CMPS
34
Compass Pathways
CMPS
$1.52B
$6.63M 0.68%
300,000
-1,100,000
-79% -$35M
LABP
35
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$6.6M 0.68%
137,500
-3,000
-2% -$315K
ALNY icon
36
Alnylam Pharmaceuticals
ALNY
$37.5B
$5.93M 0.61%
+35,000
New +$6.51M
ELDN icon
37
Eledon Pharmaceuticals
ELDN
$276M
$5.91M 0.61%
1,339,793
– –
ZGNX
38
DELISTED
Zogenix, Inc.
ZGNX
$5.69M 0.59%
+350,000
New +$5.13M
FATE icon
39
Fate Therapeutics
FATE
$280M
$5.5M 0.57%
+94,000
New +$5.33M
ARQT icon
40
Arcutis Biotherapeutics
ARQT
$3.49B
$5.18M 0.53%
+250,000
New +$4.98M
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$5.12M 0.53%
454,545
-615,000
-58% -$8.27M
LENZ
42
LENZ Therapeutics
LENZ
$182M
$5.05M 0.52%
58,044
-114,286
-66% -$9.47M
TRML
43
DELISTED
Tourmaline Bio
TRML
$5.03M 0.52%
32,901
-17,891
-35% -$2.65M
SPRB
44
Spruce Biosciences
SPRB
$121M
$4.91M 0.51%
+14,667
New +$4.37M
CGEM icon
45
Cullinan Oncology
CGEM
$1.07B
$4.45M 0.46%
288,458
– –
YMAB
46
DELISTED
Y-mAbs Therapeutics
YMAB
$4.05M 0.42%
+250,000
New +$5.34M
VTGN icon
47
VistaGen Therapeutics
VTGN
$9.23M
$3.9M 0.4%
+66,667
New +$4.34M
IMA
48
ImageneBio Inc
IMA
$63.1M
$3.76M 0.39%
24,988
– –
JANX icon
49
Janux Therapeutics
JANX
$946M
$3.65M 0.38%
185,196
-61,926
-25% -$1.3M
RAIN
50
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$3.16M 0.33%
245,161
-220,170
-47% -$3.15M
1
2
3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2021 Portfolio in Review

As of Q4 2021, Logos Global Management held 83 positions worth $970M, down 30% from $1.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Logos Global Management withdrew a net $194M in Q4 2021, closing 17 positions and reducing 23 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $62.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Ventyx Biosciences worth $36.2M.

  • Logos Global Management's largest Q4 2021 buy was Ventyx Biosciences: 1,824,280 shares worth $36.2M.
  • Logos Global Management added most to Repare Therapeutics in Q4 2021, an estimated $39.6M increase.
  • Logos Global Management's biggest Q4 2021 reduction was Compass Pathways, cutting an estimated $35M.
  • Logos Global Management fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, selling an estimated $62.9M.
  • Logos Global Management's ten largest holdings make up 49% of its $970M portfolio in Q4 2021.
  • Logos Global Management opened 26 new positions and closed 17 in Q4 2021.
  • Logos Global Management's portfolio value fell 30% quarter-over-quarter to $970M.

Based on Logos Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.